Peters A, Smythe A, Wu L, Monks A, Boyd M, Shoemaker R
NCI,FREDERICK CANC RES & DEV CTR,DIV CANC TREATMENT,DEV THERAPEUT PROGRAM,FREDERICK,MD 21702. NCI,FREDERICK CANC RES & DEV CTR,PROGRAM RESOURCES INC DYNCORP,FREDERICK,MD 21702.
Oncol Rep. 1994 Sep;1(5):907-11. doi: 10.3892/or.1.5.907.
The relationship between cellular levels of mRNA coding for DNA topoisomerase II, both the alpha and beta isoforms, and in vitro sensitivity to anticancer drugs were evaluated. Using a sensitive RNA-polymerase chain reaction technique, the levels of mRNA coding for the alpha and beta isoforms of topoisomerase II were estimated relative to beta-actin mRNA. A relatively narrow range of expression was observed across a broad range of approximately 60 human tumor cell lines representing eight major histological types which have been characterized in detail with respect to their in vitro sensitivity to standard anticancer drugs. No significant correlations were observed between mRNA level and cellular response to drugs thought to inhibit topoisomerase II or any of the other drugs studied. These results suggest that predictive tests for response to topoisomerase II-related drugs can not be based on estimation of levels of mRNA.
评估了编码DNA拓扑异构酶II的α和β两种同工型的mRNA细胞水平与体外抗癌药物敏感性之间的关系。采用灵敏的RNA聚合酶链反应技术，相对于β-肌动蛋白mRNA估算编码拓扑异构酶IIα和β同工型的mRNA水平。在大约60种代表8种主要组织学类型的人类肿瘤细胞系中观察到相对较窄的表达范围，这些细胞系在体外对标准抗癌药物的敏感性方面已得到详细表征。在mRNA水平与细胞对认为可抑制拓扑异构酶II的药物或所研究的任何其他药物的反应之间未观察到显著相关性。这些结果表明，不能基于mRNA水平的估算来进行针对拓扑异构酶II相关药物反应的预测性检测。
